Total compensation: $8,037,001 for the year ended June 30, 2019
Nonequity incentive pay: $2,008,183
Other compensation: $45,688
Value realized on vesting shares: $5,026,130
New stock options: 60,222
CEO pay ratio: 171-1
Median employee pay: $64,371
Total shareholder return: 41.9%
Note: Kummeth's compensation was the highest since he joined Minneapolis-based Bio-Techne as CEO in April 2013 — and $3.3 million more than the previous year — thanks mainly to $5 million worth of previously issued restricted stock awards that vested last year.
Under Kummeth's leadership, the maker of biotechnology reagents and instruments for research and diagnostic labs made more than a dozen acquisitions and nearly doubled its annual revenue to $714 million for the last fiscal year.
The company's share price has had a total return of 233% during his tenure, outpacing the 88% return of the S&P 500 index. That market outperformance helped increase the value of Kummeth's long-term equity awards.
Kummeth also earned his largest annual performance bonus, $2 million, a 25% increase over the previous year and 159% of the targeted amount for the year.